Please login to the form below

pacritinib

This page shows the latest pacritinib news and features for those working in and with pharma, biotech and healthcare.

CTI slumps as Servier-partnered lymphoma drug fails

Thankfully for CTI, it’s been making progress on main pipeline candidate pacritinib , an orally-active kinase inhibitor that targets JAK2, FLT3, IRAK1 and CSF1R and is in phase III testing ... Pacritinib has had its own share of problems, however,

Latest news

Baxalta and CTI complete filing for Jakafi rival in US

Myelofibrosis candidate pacritinib aiming for accelerated approval. Baxalta and CTI Biopharma have completed their rolling regulatory submission for their myelofibrosis candidate pacritinib in the US, and are aiming for accelerated approval.
Baxter and CTI's Jakafi rival clears phase III trial

Baxter licensed rights to pacritinib from CTI in 2013 in a deal valued at up to $272m deal. ... year. The trial will also compare pacritinib to best available therapy, but in this case that will include JAK2 inhibitors.
Jakafi cleared for bone marrow disorder by FDA

pacritinib. Sanofi was forced to discontinue development of its fedratinib (SAR302503) candidate after cases of a rare form of encephalopathy were seen in late-stage trials.
Baxter licenses cancer drug from CTI in $172m deal

Specifically, the company's chief executive James Bianco maintains that pacritinib is less prone to causing reductions in blood platelet counts, which can limit treatment. ... he added, noting that additional data on pacritinib will be presented at the
Sanofi pulls development of blood cancer drug

Therapeutics/Baxter's pacritinib.

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

Pharma deals in August 2015

Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib.
Deal Watch table for November 2013

232. Cell Therapeutics / Baxter. Licence. JAK2/FLT3 inhibitor pacritinib for solid tumours, joint marketing in US includes an equity purchase.
Pharma deals during November 2013

Cell Therapeutics' experimental JAK2/FLT3 inhibitor, pacritinib. ... The Sanofi decision was taken following reported cases consistent with Wernicke's encephalopathy in patients participating in the clinical trials. Pacritinib, an oral therapy, is

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Principal Medical Writer: Varies on experience

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Account Management: Competitive Salary Offered

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Content Editor - Biotechnology: Salary TBC

PMHub

Add my company

fox&cat

up to your ears in it? some pressure is helpful but too much of the wrong sort quickly takes its...

Latest intelligence

WHITE PAPER: Why do men die younger?: It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
3 tips to show patient diversity in your clinical trial materials: Here are some useful tips to help get your hands on authentically diverse stock photos....
Virtual congresses: video thrilled the cardio tsar: Chris Ross explores the key learnings from a year of virtual congresses...